The innate immune system treats double-stranded RNA as a danger signal, which is precisely why many tumours work hard to suppress it. Researchers at the Cancer Science Institute of Singapore at NUS have identified a previously unrecognised participant in that suppression: the RNA helicase DDX6. Working in concert with the RNA-editing enzyme ADAR1, DDX6 dampens the double-stranded RNA signal that would otherwise mark a cancer cell as abnormal and invite immune attack.
The study also unsettles a long-held assumption in the field. RNA editing has generally been understood to weaken double-stranded RNA structures, and therefore to mute the alarm. The team found that certain editing events do the opposite, strengthening those structures, and that DDX6 acts to prevent such events from occurring. That reframes ADAR1 biology, which has become a prominent target in cancer immunology, as something more conditional than a simple switch.
Functional experiments support the mechanistic account. In laboratory work, removing DDX6 restored immune signalling and slowed tumour growth, the pattern expected if the helicase is genuinely holding the alarm down rather than acting incidentally. The findings were published in Science Immunology, and the group is now searching both for molecules capable of blocking DDX6 and for other proteins operating in the same pathway.
For investigators pursuing immunotherapy targets, the appeal of a node like DDX6 is that it acts on the tumour's capacity to hide rather than on the immune cell's capacity to attack. Many solid cancers resist checkpoint blockade because they present too little for the immune system to recognise. Restoring an intrinsic danger signal offers a different point of leverage, and one that may combine usefully with existing agents.